Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

BACKGROUND: The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients. Similarly to...

Descripción completa

Detalles Bibliográficos
Autores principales: La Monica, Silvia, Minari, Roberta, Cretella, Daniele, Flammini, Lisa, Fumarola, Claudia, Bonelli, Mara, Cavazzoni, Andrea, Digiacomo, Graziana, Galetti, Maricla, Madeddu, Denise, Falco, Angela, Lagrasta, Costanza Annamaria, Squadrilli, Anna, Barocelli, Elisabetta, Romanel, Alessandro, Quaini, Federico, Petronini, Pier Giorgio, Tiseo, Marcello, Alfieri, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537372/
https://www.ncbi.nlm.nih.gov/pubmed/31138260
http://dx.doi.org/10.1186/s13046-019-1240-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537372/
https://www.ncbi.nlm.nih.gov/pubmed/31138260
http://dx.doi.org/10.1186/s13046-019-1240-x

Ejemplares similares